[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610717":3},{"organization":4,"armGroups":7,"interventions":42,"overallOfficials":36,"centralContacts":51,"locations":60,"responsibleParty":82,"collaborators":36,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":36,"eligibilityCriteria":90,"healthyVolunteers":86,"sex":91,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":36,"studyType":97,"phases":98,"briefSummary":101,"conditions":102,"keywords":36,"overallStatus":63,"whyStopped":36,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Shanghai Shengdi Pharmaceutical Co., Ltd","INDUSTRY",[8,14,18,22,26,30,34,39],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1 Group","EXPERIMENTAL","SHR-4610 dose A in dose escalation stage.",[13],"Drug: SHR-4610 Injection",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2 Group","SHR-4610 dose B in dose escalation stage.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3 Group","SHR-4610 dose C in dose escalation stage.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Cohort 4 Group","SHR-4610 dose D in dose escalation stage.",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Cohort 5 Group","SHR-4610 dose A\u002FB\u002FC\u002FD in dose expansion stage.",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"Cohort 6 Group","SHR-4610 dose A\u002FB\u002FC\u002FD in efficacy expansion stage.",[13],{"label":35,"type":10,"description":36,"interventionNames":37},"Cohort 7：SHR-4610 dose D +SHR-A1811 dose A in Satefy run in Stage",null,[13,38],"Drug: SHR-A1811 for injection",{"label":40,"type":10,"description":36,"interventionNames":41},"Cohort 8：SHR-4610 dose D+SHR-A1811 dose A in Satefy run in Efficacy expansion stage",[13,38],[43,48],{"type":44,"name":45,"description":46,"armGroupLabels":47,"otherNames":36},"DRUG","SHR-4610 Injection","SHR-4610 injection",[9,15,19,23,27,31,35,40],{"type":44,"name":49,"description":49,"armGroupLabels":50,"otherNames":36},"SHR-A1811 for injection",[35,40],[52,57],{"name":53,"role":54,"phone":55,"phoneExt":36,"email":56},"Yunpeng Jin","CONTACT","+86-021-61053363","yunpeng.jin.yj1@hengrui.com",{"name":58,"role":54,"phone":55,"phoneExt":36,"email":59},"Yuting Wang","yuting.wang@hengrui.com",[61],{"facility":62,"status":63,"city":64,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"Zhejiang Cancer Hospital","RECRUITING","Hangzhou","Zhejiang","310022","China","CN",{"type":70,"coordinates":71},"Point",[72,73],120.16142,30.29365,{"lat":73,"lon":72},[76,80],{"name":77,"role":54,"phone":78,"phoneExt":36,"email":79},"Xiangdong Cheng","+86-0571-88888888","Chengxd1316@126.com",{"name":77,"role":81,"phone":36,"phoneExt":36,"email":36},"PRINCIPAL_INVESTIGATOR",{"type":83,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR","100610717","phase-1-a-study-of-shr-4610-injection-in-patients-with-advanced-solid-tumors-100610717",false,"NCT07231211","A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors","An Open-label, Multicenter Phase I\u002FII Clinical Study of SHR-4610 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy","Inclusion Criteria:\n\n1. Subjects must voluntarily agree to participate in the trial and sign a written informed consent form;\n2. Age range: 18-75 years old, both male and female are welcome;\n3. Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors which is relapsed or refractory to standard treatment, or lack of standard treatment;\n4. Have at least one measurable tumor lesion per RECIST v1.1;\n5. ECOG performance status of 0-1;\n6. Life expectancy ≥ 12 weeks;\n7. Adequate bone marrow and organ function.\n\nExclusion Criteria:\n\n1. Patients with active central nervous system metastases or meningeal metastases;\n2. Systemic antitumor therapy was received 4 weeks before the start of the study;\n3. Moderate or severe ascites with clinical symptoms; Uncontrolled or moderate or higher pleural effusion or pericardial effusion;\n4. Have poorly controlled or severe cardiovascular disease;\n5. Subjects with active hepatitis B or active hepatitis C;\n6. Adverse reactions of previous anti-tumor treatment have not recovered to Grade ≤ 1 per NCI-CTCAE v5.0.","ALL","18 Years","75 Years",{"count":95,"type":96},258,"ESTIMATED","INTERVENTIONAL",[99,100],"PHASE1","PHASE2","This study is an open, multicenter Phase I\u002FII clinical trial, divided into two stages: dose exploration (including dose escalation and dose extension) and efficacy extension.",[103],"Solid Tumors","2026-08-13",{"date":106,"type":107},"2026-08-17","ACTUAL",{"date":109,"type":107},"2025-11-20",{"date":111,"type":96},"2027-12",{"name":5,"class":6},1]